Immunotherapy with adoptively transferred T cells has recently reached tremendous success. Here, the therapeutic potential of transgenic, antigen-specific, allogeneic HLA-A*02:01-restricted cytotoxic T cells directed against the Ewing Sarcoma specific target antigen STEAP1 was examined in vitro as well as in an immunodeficient mouse model. The TCR transgenic T cells show STEAP1 specific recognition and lysis of target cells in an HLA-A*02:01 restricted manner. Additionally, those cells inhibit growth of Ewing Sarcoma cells in vivo more effectively than unspecific T cells.
«
Immunotherapy with adoptively transferred T cells has recently reached tremendous success. Here, the therapeutic potential of transgenic, antigen-specific, allogeneic HLA-A*02:01-restricted cytotoxic T cells directed against the Ewing Sarcoma specific target antigen STEAP1 was examined in vitro as well as in an immunodeficient mouse model. The TCR transgenic T cells show STEAP1 specific recognition and lysis of target cells in an HLA-A*02:01 restricted manner. Additionally, those cells inhibit g...
»